Showing results (71-80 of 90) with videos related to
Sort By:
Pageof 9
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 8, 2020
Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatmentAshley N Siegel, Nelson Rodrigues, Flora Nasri, et al.Journal of Affective Disorders|September 19, 2024
Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic reviewGia Han Le, Sabrina Wong, Andy Lu, et al.JAMA Psychiatry|July 28, 2021
Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysisFelicia Ceban, Danica Nogo, Isidro P Carvalho, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.Infectious Diseases (London, England)|March 14, 2022
Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for researchFelicia Ceban, Alexia Leber, Muhammad Youshay Jawad, et al.Journal of Psychiatric Research|June 18, 2023
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic reviewDaniel H Cooper, Ranuk Ramachandra, Felicia Ceban, et al.Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.Pageof 9